iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Empirical Asset Management LLC

Empirical Asset Management LLC reduced its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 6.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 13,731 shares of the financial services provider’s stock after selling 927 shares during the quarter. Empirical Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $1,815,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the third quarter worth $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter valued at $36,000. Modus Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. purchased a new position in iShares Biotechnology ETF in the 3rd quarter worth about $59,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ:IBB opened at $132.65 on Friday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The firm has a 50 day simple moving average of $136.62 and a 200 day simple moving average of $141.77.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.